A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 2, 2011, Pages 91-103

  Sasaki, Takahiko ^a   Nakayama, Katsutoshi ^b   Yasuda, Hiroyasu ^c   Yamaya, Mutsuo ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

chronic obstructive pulmonary disease (COPD); common cold; exacerbations; proton pump inhibitors (PPIs); rhinovirus

Indexed keywords

BAFILOMYCIN A1; CLOPIDOGREL; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 AGONIST; VANILLOID RECEPTOR AGONIST;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BRONCHOSPASM; CELL PROTECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMON COLD; COUGHING; CUSHING DISEASE; DISEASE EXACERBATION; DRUG MECHANISM; DRUG METABOLISM; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERACTIVITY; HYPERSECRETION; MICROVASCULAR LEAKAGE; OXIDATIVE STRESS; PEPTIC ULCER; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; RHINOVIRUS INFECTION; SECRETION; SIDE EFFECT; VASCULAR DISEASE; ACUTE DISEASE; DRUG EFFECT; PICORNAVIRUS INFECTION; RHINOVIRUS; VIROLOGY;

ACUTE DISEASE; HUMANS; PICORNAVIRIDAE INFECTIONS; PROTON PUMP INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RHINOVIRUS;

EID: 79953326956     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465810392264     Document Type: Review

References (89)

1. Alfageme I. Vazquez R. Reyes N. Munoz J. Fernandez A. Hernandez M. (2006) Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61: 189–195.
2. Angiolillo D.J. Fernandez-Ortiz A. Bernardo E. Alfonso F. Macaya C. Bass T.A. (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49: 1505–1516.
3. Bayer N. Schober D. Prchla E. Murphy R.F. Blaas D. Fuchs R. (1998) Effect of bafilomycin A1 and nocodazole on endocytic transport in hela cells: implications for viral uncoating and infection. J Virol 72: 9645–9655.
4. Becker J.C. Grosser N. Waltke C. Schulz S. Erdmann K. Domschke W. (2006) Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 345: 1014–1021.
5. Betz R. Kohlhaufl M. Kassner G. Mullinger B. Maier K. Brand P. (2001) Increased sputum IL-8 and IL-5 in asymptomatic nonspecific airway hyperresponsiveness. Lung 179: 119–133.
6. Burge P.S. Calverley P.M. Jones P.W. Spencer S. Anderson J.A. Maslen T.K. (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE Trial. BMJ 320: 1297–1303.
7. Calverley P.M. Anderson J.A. Celli B. Ferguson G.T. Jenkins C. Jones P.W. (2007a) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775–789.
8. Calverley P.M. Rabe K.F. Goehring U.M. Kristiansen S. Fabbri L.M. Martinez F.J. (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685–694.
9. Calverley P.M. Sanchez-Toril F. McIvor A. Teichmann P. Bredenbroeker D. Fabbri L.M. (2007b) Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176: 154–161.
10. Carlsson R. Fandriks L. Jonsson C. Lundell L. Orlando R.C. (1999) Is the esophageal squamous epithelial barrier function impaired in patients with gastroesophageal reflux disease? Scand J Gastroenterol 34: 454–458.
11. Casasnovas J.M. Springer T.A. (1994) Pathway of rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released. J Virol 68: 5882–5889.
12. Cholongitas E. Pipili C. Dasenaki M. Goudras S. (2008) Are upper gastrointestinal symptoms associated with exacerbations of COPD? Int J Clin Pract 62: 967–967.
13. Clemencon G.H. Osterman P.O. (1961) Hiatal hernia in bronchial asthma: the importance of concomitant pulmonary emphysema. Gastroenterologia 95: 110–120.
14. Crowell M.D. Zayat E.N. Lacy B.E. Schettler-Duncan A. Liu M.C. (2001) The effects of an inhaled beta(2)-adrenergic agonist on lower esophageal function: a dose–response study. Chest 120: 1184–1189.
15. Decramer M. Celli B. Kesten S. Lystig T. Mehra S. Tashkin D.P. (2009) Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 374: 1171–1178.
16. Doherty M.J. Mister R. Pearson M.G. Calverley P.M. (2000) Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease. Thorax 55: 643–649.
17. Donaldson G.C. Seemungal T.A. Bhowmik A. Wedzicha J.A. (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847–852.
18. Dublin S. Walker R.L. Jackson M.L. Nelson J.C. Weiss N.S. Jackson L.A. (2010) Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case–control study. Pharmacoepidemiol Drug Saf 19: 792–802.
19. D'urzo A. Jugovic P. (2002) Chronic cough. Three most common causes. Can Fam Physician 48: 1311–1316.
20. Fournier M.R. Targownik L.E. Leslie W.D. (2009) Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas 64: 9–13.
21. Furukawa E. Ohrui T. Yamaya M. Suzuki T. Nakasato H. Sasaki T. (2004) Human airway submucosal glands augment eosinophil chemotaxis during rhinovirus infection. Clin Exp Allergy 34: 704–711.
22. Furuta T. Ohashi K. Kamata T. Takashima M. Kosuge K. Kawasaki T. (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129: 1027–1030.
23. Furuta T. Shirai N. Watanabe F. Honda S. Takeuchi K. Iida T. (2002) Effect of cytochrome P4502c19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72: 453–460.
24. Garcia Rodríguez L.A. Ruigomez A. Martin-Merino E. Johansson S. Wallander M.A. (2008) Relationship between gastroesophageal reflux disease and COPD in UK primary care. Chest 134: 1223–1230.
25. Geppetti P. Trevisani M. (2004) Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. Br J Pharmacol 141: 1313–1320.
26. Guenegou A. Leynaert B. Benessiano J. Pin I. Demoly P. Neukirch F. (2006) Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France. J Med Genet 43: e43–e43.
27. Gulmez S.E. Holm A. Frederiksen H. Jensen T.G. Pedersen C. Hallas J. (2007) Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch Intern Med 167: 950–955.
28. Hadfield A.T. Lee W. Zhao R. Oliveira M.A. Minor I. Rueckert R.R. (1997) The refined structure of human rhinovirus 16 at 2.15 a resolution: implications for the viral life cycle. Structure 5: 427–441.
29. Hakonarson H. Maskeri N. Carter C. Hodinka R.L. Campbell D. Grunstein M.M. (1998) Mechanism of rhinovirus-induced changes in airway smooth muscle responsiveness. J Clin Invest 102: 1732–1741.
30. Handa O. Yoshida N. Fujita N. Tanaka Y. Ueda M. Takagi T. (2006) Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res 55: 476–480.
31. Harding S.M. (2003) Recent clinical investigations examining the association of asthma and gastroesophageal reflux. Am J Med 115(Suppl. 3A): 39S–44S.
32. Hendley J.O. (1999) Clinical virology of rhinoviruses. Adv Virus Res 54: 453–466.
33. Hermansen M.N. Nielsen K.G. Buchvald F. Jespersen J.J. Bengtsson T. Bisgaard H. (2006) Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma. Chest 129: 1203–1209.
34. Heymann P.W. Platts-Mills T.A. Johnston S.L. (2005) Role of viral infections, atopy and antiviral immunity in the etiology of wheezing exacerbations among children and young adults. Pediatr Infect Dis J 24: S217's222.
35. Hirai H. Kubo H. Yamaya M. Nakayama K. Numasaki M. Kobayashi S. (2003) Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines. Blood 102: 1619–1621.
36. Hogg J.C. Chu F. Utokaparch S. Woods R. Elliott W.M. Buzatu L. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645–2653.
37. Hosoda M. Yamaya M. Suzuki T. Yamada N. Kamanaka M. Sekizawa K. (2002) Effects of rhinovirus infection on histamine and cytokine production by cell lines from human mast cells and basophils. J Immunol 169: 1482–1491.
38. Hulot J.S. Collet J.P. Silvain J. Pena A. Bellemain-Appaix A. Barthelemy O. (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2c19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 56: 134–143.
39. Hungin A.P. Raghunath A.S. Wiklund I. (2005) Beyond heartburn: a systematic review of the extra-oesophageal spectrum of reflux-induced disease. Fam Pract 22: 591–603.
40. Inglis T.J. Sherratt M.J. Sproat L.J. Gibson J.S. Hawkey P.M. (1993) Gastroduodenal dysfunction and bacterial colonisation of the ventilated lung. Lancet 341: 911–913.
41. Inoue D. Yamaya M. Kubo H. Sasaki T. Hosoda M. Numasaki M. (2006) Mechanisms of mucin production by rhinovirus infection in cultured human airway epithelial cells. Respir Physiol Neurobiol 154: 484–499.
42. Ishizuka S. Yamaya M. Suzuki T. Takahashi H. Ida S. Sasaki T. (2003) Effects of rhinovirus infection on the adherence of streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis 188: 1928–1939.
43. Kountouras J. Boura P. Lygidakis N.J. (2000) Omeprazole and regulation of cytokine profile in Helicobacter pylori-infected patients with duodenal ulcer disease. Hepatogastroenterology 47: 1301–1304.
44. Lazenby J.P. Guzzo M.R. Harding S.M. Patterson P.E. Johnson L.F. Bradley L.A. (2002) Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest 121: 625–634.
45. Lundberg J.M. Saria A. (1983) Capsaicin-induced desensitization of airway mucosa to cigarette smoke, mechanical and chemical irritants. Nature 302: 251–253.
46. Mosser A.G. Sgro J.Y. Rueckert R.R. (1994) Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J Virol 68: 8193–8201.
47. Murphy T.F. (2006) The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 19: 225–230.
48. Nakamura K. Goto F. Ray W.A. McAllister C.B. Jacqz E. Wilkinson G.R. (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408.
49. Niewoehner D.E. Rice K. Cote C. Paulson D. Cooper J.A. Jr Korducki L. (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143: 317–326.
50. Ochiai H. Sakai S. Hirabayashi T. Shimizu Y. Terasawa K. (1995) Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Antiviral Res 27: 425–430.
51. Ohara T. Arakawa T. (1999) Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci 44: 1710–1715.
52. Ohrui T. Yamaya M. Sekizawa K. Yamada N. Suzuki T. Terajima M. (1998) Effects of rhinovirus infection on hydrogen peroxide-induced alterations of barrier function in the cultured human tracheal epithelium. Am J Respir Crit Care Med 158: 241–248.
53. Papadopoulos N.G. Papi A. Meyer J. Stanciu L.A. Salvi S. Holgate S.T. (2001) Rhinovirus infection up-regulates eotaxin and eotaxin-2 expression in bronchial epithelial cells. Clin Exp Allergy 31: 1060–1066.
54. Perez L. Carrasco L. (1993) Entry of poliovirus into cells does not require a low-pH step. J Virol 67: 4543–4548.
55. Prchla E. Kuechler E. Blaas D. Fuchs R. (1994) Uncoating of human rhinovirus serotype 2 from late endosomes. J Virol 68: 3713–3723.
56. Rabe K.F. Hurd S. Anzueto A. Barnes P.J. Buist S.A. Calverley P. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 176: 532–555.
57. Rascon-Aguilar I.E. Pamer M. Wludyka P. Cury J. Coultas D. Lambiase L.R. (2006) Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 130: 1096–1101.
58. Rennard S.I. Schachter N. Strek M. Rickard K. Amit O. (2006) Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129: 56–66.
59. Sabolic I. Brown D. Verbavatz J.M. Kleinman J. (1994) H(+)-atpases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am J Physiol 266: F868–F877.
60. Sachs G. Prinz C. Loo D. Bamberg K. Besancon M. Shin J.M. (1994) Gastric acid secretion: activation and inhibition. Yale J Biol Med 67: 81–95.
61. Sarkar M. Hennessy S. Yang Y.X. (2008) Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 149: 391–398.
62. Sasaki T. Nakayama K. Yasuda H. Yoshida M. Asamura T. Ohrui T. (2009) A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc 57: 1453–1457.
63. Sasaki T. Yamaya M. Yasuda H. Inoue D. Yamada M. Kubo H. (2005) The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol 509: 201–210.
64. Savolainen C. Blomqvist S. Mulders M.N. Hovi T. (2002) Genetic clustering of all 102 human rhinovirus prototype strains: serotype 87 is close to human enterovirus 70. J Gen Virol 83: 333–340.
65. Seemungal T. Harper-Owen R. Bhowmik A. Moric I. Sanderson G. Message S. (2001) Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 1618–1623.
66. Seemungal T.A. Wilkinson T.M. Hurst J.R. Perera W.R. Sapsford R.J. Wedzicha J.A. (2008) Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 178: 1139–1147.
67. Sethi S. (2004) New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 17: 113–119.
68. Sethi S. Murphy T.F. (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359: 2355–2365.
69. Smith C.B. Golden C.A. Kanner R.E. Renzetti A.D. Jr (1980) Association of viral and mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 121: 225–232.
70. Sontag S.J. O'connell S. Khandelwal S. Miller T. Nemchausky B. Schnell T.G. (1990) Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 99: 613–620.
71. Soriano J.B. Visick G.T. Muellerova H. Payvandi N. Hansell A.L. (2005) Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 128: 2099–2107.
72. Subauste M.C. Jacoby D.B. Richards S.M. Proud D. (1995) infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest 96: 549–557.
73. Suzuki T. Yanai M. Yamaya M. Satoh-Nakagawa T. Sekizawa K. Ishida S. (2001) Erythromycin and common cold in COPD. Chest 120: 730–733.
74. Targownik L.E. Lix L.M. Metge C.J. Prior H.J. Leung S. Leslie W.D. (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179: 319–326.
75. Tashkin D.P. Celli B. Senn S. Burkhart D. Kesten S. Menjoge S. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543–1554.
76. Tatsumi K. Fukuchi Y. (2007) Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 55: 1884–1886.
77. Terada K. Muro S. Sato S. Ohara T. Haruna A. Marumo S. (2008) Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 63: 951–955.
78. Terajima M. Yamaya M. Sekizawa K. Okinaga S. Suzuki T. Yamada N. (1997) Rhinovirus infection of primary cultures of human tracheal epithelium: role of ICAM-1 and IL-1beta. Am J Physiol 273: L749–L759.
79. Thorens J. Froehlich F. Schwizer W. Saraga E. Bille J. Gyr K. (1996) Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 39: 54–59.
80. Verdaguer N. Blaas D. Fita I. (2000) Structure of human rhinovirus serotype 2 (HRV2). J Mol Biol 300: 1179–1194.
81. Watanabe T. Higuchi K. Tominaga K. Fujiwara Y. Arakawa T. (2001) Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta. Gut 48: 774–781.
82. Wedzicha J.A. Seemungal T.A. (2007) COPD exacerbations: defining their cause and prevention. Lancet 370: 786–796.
83. Wongsurakiat P. Maranetra K.N. Wasi C. Kositanont U. Dejsomritrutai W. Charoenratanakul S. (2004) Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 125: 2011–2020.
84. Xing L. Casasnovas J.M. Cheng R.H. (2003) Structural analysis of human rhinovirus complexed with ICAM-1 reveals the dynamics of receptor-mediated virus uncoating. J Virol 77: 6101–6107.
85. Yamada N. Yamaya M. Okinaga S. Nakayama K. Sekizawa K. Shibahara S. (2000) Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 66: 187–195.
86. Yasuda H. Yamaya M. Nakayama K. Ebihara S. Sasaki T. Okinaga S. (2005) Increased arterial carboxyhemoglobin concentrations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 1246–1251.
87. Zhao R. Pevear D.C. Kremer M.J. Giranda V.L. Kofron J.A. Kuhn R.J. (1996) Human rhinovirus 3 at 3.0 a resolution. Structure 4: 1205–1220.
88. Zheng J.P. Kang J. Huang S.G. Chen P. Yao W.Z. Yang L. (2008) Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (Peace Study): a randomised placebo-controlled study. Lancet 371: 2013–2018.
89. Zhu Z. Tang W. Ray A. Wu Y. Einarsson O. Landry M.L. (1996) Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation. J Clin Invest 97: 421–430.